-

IFF to Release Fourth Quarter & Full Year 2024 Results on Feb. 18, 2025; IFF to Present at 2025 CAGNY Conference on Feb. 20, 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2024 earnings results following the market close on Tuesday, Feb. 18, 2025. The management team will host a live webcast on Wednesday, Feb. 19, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community.

IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 20, 2025 at 1:00 PM ET.

Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

Industry:

IFF

NYSE:IFF
Release Versions
English
$Cashtags
$IFF

Contacts

Media Relations:
Paulina Heinkel
332.877.5339
Media.request@iff.com

Investor Relations:
Michael Bender
212.708.7263
Investor.Relations@iff.com

More News From IFF

IFF and Kemira Form Joint Venture To Produce Sustainable Biobased Materials at Scale

NEW YORK--(BUSINESS WIRE)--IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio’s production wi...

IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025

TOKYO--(BUSINESS WIRE)--IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11. “IFF Pharma Solutions is committed to redefining drug delivery through material science innovation,” said Frank Zhao, commercial leader, IFF Phar...

IFF Declares Dividend for First Quarter 2025

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 11, 2025 to shareholders of record as of March 21, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—ad...
Back to Newsroom
  1. There was an issue with the authorization server. Please contact support if the issue persists.